Study guide
11.1 Critical Illness, Sepsis & Trauma Nutrition
Certified Nutrition Support Clinician CNSC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements
1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry
2 Chapter 2: Macronutrients, Micronutrients & Fluid Management
2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements
3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus
3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria
4 Chapter 4: Pediatric & Specialized Nutrition Assessment
4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation
5 Chapter 5: Enteral Nutrition Access & Tube Management
5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care
6 Chapter 6: Enteral Formulation, Regimen Design & Administration
6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements
7 Chapter 7: Enteral Complications & Medication Administration
7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery
8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design
8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation
9 Chapter 9: Parenteral Additives, Compounding & Physical Stability
9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration
10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities
10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease
11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support
11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment
12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support
12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure
13 Chapter 13: Oncology, Surgical Care & Intestinal Failure
13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption
14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support
14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education
15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care
15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence
11.1 Critical Illness, Sepsis & Trauma Nutrition
Key Takeaways Explain This Topic AI
The metabolic stress response follows a triphasic trajectory: the initial Ebb phase (first 24–48 hours) marked by hemodynamic instability, shock, and depressed metabolic rate; the Flow phase characterized by profound hypermetabolism, accelerated proteolysis, and insulin resistance; and the Recovery phase of anabolic rebuilding.
SCCM/ASPEN clinical guidelines mandate initiating early enteral nutrition (EN) within 24–48 hours of ICU admission once the patient is hemodynamically resuscitated, to preserve gut mucosal integrity, support gut-associated lymphoid tissue (GALT), and reduce systemic infections.
Patients at high nutritional risk (identified by a NUTRIC score ≥ 5 \ge 5 ≥ 5 without IL-6 or NRS-2002 ≥ 5 \ge 5 ≥ 5 ) must be prioritized for early, proactive nutrition support, whereas low-risk patients tolerate delayed or trophic feeding during the initial week of critical illness.
For mechanically ventilated adults in the first 7 to 10 ICU days, the 2021 ASPEN guideline supports an individualized energy range of about 12 to 25 kcal/kg/day; trials do not show a clear outcome advantage for forcing early goal energy over lower-energy feeding.
Hold enteral nutrition during uncontrolled shock or escalating vasopressors. Once resuscitated and stable, begin cautiously; do not use immune-modulating formulas routinely in severe sepsis, and avoid supplemental high-dose glutamine in multi-organ failure.
Last updated: October 2026
11.1 Critical Illness, Sepsis & Trauma Nutrition
Clinical Core: The systemic response to severe trauma, burn injury, and septic shock is characterized by profound neuroendocrine and metabolic dysregulation. Clinicians must distinguish the initial hypoperfused, hypometabolic Ebb phase (first 24 to 48 hours)—where hemodynamic resuscitation takes absolute precedence over nutrition—from the hyperdynamic, hypercatabolic Flow phase , marked by unsuppressible hepatic gluconeogenesis, extensive skeletal muscle proteolysis, and severe peripheral insulin resistance. According to SCCM/ASPEN critical care nutrition guidelines, early enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission once volume resuscitation is established. High-risk patients (NUTRIC score ≥ 5 \ge 5 ≥ 5 or NRS-2002 ≥ 5 \ge 5 ≥ 5 ) derive the greatest benefit from prompt feeding. In hemodynamic instability, EN is strictly held during active shock (MAP < 65 mmHg < 65\text{ mmHg} < 65 mmHg or escalating pressors) due to non-occlusive mesenteric ischemia risk, but trophic feeds may proceed cautiously on low-dose stable vasopressors. Immune-modulating formulas are not recommended routinely in severe sepsis, and supplemental high-dose glutamine should be avoided in multi-organ dysfunction because trials found harm.
The Neuroendocrine Stress Response: Ebb, Flow, and Recovery Phases
In 1942, Sir David Cuthbertson first characterized the biphasic systemic response to physical injury, which contemporary critical care medicine categorizes into three distinct physiological periods: the Ebb phase , the Flow (catabolic) phase , and the Recovery (anabolic) phase . [ TRAUMATIC INSULT / SEVERE SEPSIS ]
- │
- ▼
- ┌───────────────────────────────────────────────────────────────────────┐
- │ 1. EBB PHASE (First 24–48 Hours) │
- │ • Hypovolemic shock, tissue hypoperfusion, cellular hypoxia │
- │ • Depressed metabolic rate, low VO2, hypothermia, low cardiac output │
- │ • Neuroendocrine surge: Epinephrine, Norepinephrine, Cortisol, ADH │
- │ • PRIORITY: Hemodynamic resuscitation; ENTERAL NUTRITION WITHHELD │
- └───────────────────────────────────┬───────────────────────────────────┘
- │ (Fluid & Hemodynamic Resuscitation)
- ▼
- ┌───────────────────────────────────────────────────────────────────────┐
- │ 2. FLOW PHASE — CATABOLIC SUBPHASE (Days to Weeks) │
- │ • Hyperdynamic cardiovascular state: Tachycardia, high cardiac output │
- │ • Hypermetabolism: Elevated VO2, elevated REE (+20% to +100%) │
- │ • Unsuppressible hepatic gluconeogenesis & extreme insulin resistance │
- │ • Massive skeletal muscle proteolysis (ubiquitin-proteasome pathway) │
- │ • PRIORITY: Early EN within 24–48h; high protein; avoid overfeeding │
- └───────────────────────────────────┬───────────────────────────────────┘
- │ (Infection Control & Wound Healing)
- ▼
- ┌───────────────────────────────────────────────────────────────────────┐
- │ 3. RECOVERY / ANABOLIC PHASE (Weeks to Months) │
- │ • Normalization of hormone levels; inflammatory cytokines dissipate │
- │ • Restoration of insulin sensitivity; positive nitrogen balance │
- │ • Tissue repair, muscle rebuilding, physical rehabilitation │
- └───────────────────────────────────────────────────────────────────────┘
- 1. The Ebb Phase (Initial 24 to 48 Hours)
Pathophysiological Derangements: Immediate response to severe burn, hemorrhagic shock, polytrauma, or acute pancreatitis. Manifested by hypovolemia, decreased central venous pressure, systemic hypoperfusion, lactic acidosis, decreased cardiac output, and reduced cellular oxygen consumption ( V O 2 V_{\text{O}_2} V O 2 ). Core body temperature and resting energy expenditure (REE) are characteristically depressed.
Endocrine Drivers: Massive sympathetic nervous system discharge triggers an abrupt surge in catecholamines (epinephrine, norepinephrine), cortisol, renin-angiotensin-aldosterone, and antidiuretic hormone (ADH) to preserve intravascular volume and perfusion to the brain and myocardium.
Clinical Rule: Enteral nutrition is strictly contraindicated during the Ebb phase. The splanchnic circulation is vasoconstricted; delivering nutrients into an under-perfused gastrointestinal tract triggers bowel distension, non-occlusive bowel ischemia, and transmural necrosis. The sole clinical priority is aggressive volume repletion, surgical hemorrhage control, and restoration of tissue microperfusion.
2. The Flow Phase (Catabolic Stage)
Pathophysiological Derangements: Commences once volume resuscitation restores macrovascular and microvascular perfusion. Characterized by a hyperdynamic cardiovascular state (high cardiac index, tachycardia, widened pulse pressure), pyrexia, increased systemic oxygen delivery and consumption, and elevated resting energy expenditure (often 20 % to 50 % 20\%\text{ to }50\% 20% to 50% above baseline, and up to 100 % 100\% 100% in severe thermal injuries).
Cytokine and Endocrine Cascades: Sustained by pro-inflammatory cytokines—primarily Tumor Necrosis Factor-alpha ( TNF − α \text{TNF}-\alpha TNF − α ), Interleukin-1 ( IL − 1 \text{IL}-1 IL − 1 ), and Interleukin-6 ( IL − 6 \text{IL}-6 IL − 6 )—acting synergistically with persistent elevations in cortisol, glucagon, and catecholamines.
Uncontrolled Hepatic Gluconeogenesis: Cortisol and glucagon upregulate phosphoenolpyruvate carboxykinase (PEPCK), driving autonomous hepatic glucose production ( 3 – 5 mg/kg/min 3\text{--}5\text{ mg/kg/min} 3 – 5 mg/kg/min ). Unlike simple fasting or starvation, this gluconeogenesis is completely unsuppressed by exogenous carbohydrate or intravenous insulin infusions .
Accelerated Proteolysis: Cytokines and glucocorticoids activate the ATP-dependent ubiquitin-proteasome pathway in skeletal muscle. Somatic protein breakdown increases exponentially, releasing large quantities of branched-chain amino acids (BCAAs) for local oxidation, while alanine and glutamine are exported to the liver for gluconeogenesis and acute-phase protein synthesis (e.g., C-reactive protein, ferritin, fibrinogen) at the expense of visceral transport proteins (albumin, prealbumin, transferrin). Daily skeletal muscle losses can reach 1.0 to 1.5 kg 1.0\text{ to }1.5\text{ kg} 1.0 to 1.5 kg of lean tissue per day ( 15 to 25 g 15\text{ to }25\text{ g} 15 to 25 g of urinary nitrogen loss daily).
Insulin Resistance: Post-receptor signaling defects in skeletal muscle and adipose tissue suppress GLUT-4 transporter translocation, resulting in profound stress-induced hyperglycemia ( > 180 mg/dL > 180\text{ mg/dL} > 180 mg/dL ), which impairs neutrophil phagocytosis, elevates oxidative stress, and multiplies nosocomial infection rates.
3. The Recovery / Anabolic Phase
Characterized by resolution of systemic inflammatory cascades, restoration of microvascular integrity, falling circulating counter-regulatory hormones, and normalization of blood glucose. Muscle catabolism ceases, and net nitrogen balance turns positive, permitting muscular hypertrophy and functional rehabilitation provided adequate substrate and physical therapy are supplied.
Clinical Parameter Ebb Phase (First 24–48 Hours) Flow Phase (Catabolic) Recovery Phase (Anabolic)
Cardiovascular State Hypodynamic; low cardiac output Hyperdynamic; high cardiac output Normalizing hemodynamics
Oxygen Consumption ( V O 2 V_{\text{O}_2} V O 2 ) Depressed / Subnormal Markedly elevated Normal baseline
Metabolic Rate (REE) Decreased Elevated ( + 20 % to + 100 % +20\%\text{ to }+100\% + 20% to + 100% ) Gradual return to baseline
Glycemia Normal or transient hyperglycemia Severe stress hyperglycemia Normalizing insulin sensitivity
Nitrogen Balance Slightly negative Severely negative ( − 15 to − 25 g/day -15\text{ to }-25\text{ g/day} − 15 to − 25 g/day ) Neutral to positive ( + 2 to + 5 g/day +2\text{ to }+5\text{ g/day} + 2 to + 5 g/day )
Primary Goal Hemodynamic resuscitation & MAP ≥ 65 \ge 65 ≥ 65 Organ support; early EN; high protein Anabolic rebuilding; physical therapy
2016 SCCM/ASPEN Guidelines: Early Enteral Feeding
The Society of Critical Care Medicine (SCCM) and the American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines mandate that enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission in critically ill patients who cannot maintain oral intake, once hemodynamic stability has been achieved.
Physiological Mechanisms of Early Enteral Delivery
Preservation of Mucosal Architecture: Luminal nutrients provide direct fuel (butyrate, glutamine, ketone bodies) to enterocytes and colonocytes, stimulating brush-border blood flow, cell turnover, and preventing villous atrophy.
Maintenance of Tight Junctions: Luminal feeding prevents the breakdown of zonula occludens-1 (ZO-1) and occludin complexes, mitigating mucosal hyperpermeability ("leaky gut").
Support of GALT and MALT: Approximately 70 % 70\% 70% of the body's immune cells reside in gut-associated lymphoid tissue (GALT). Luminal stimulation drives the synthesis and transcytosis of secretory Immunoglobulin A (sIgA) , which neutralizes luminal pathogens and toxins.
Prevention of Bacterial Translocation: In the absence of luminal nutrients, intestinal bacteria adhere to mucosal surfaces and translocate across compromised epithelial barriers into mesenteric lymph nodes and portal circulation, igniting systemic inflammatory response syndrome (SIRS) and distant organ failure.
Enteral Versus Parenteral Nutrition in Critical Illness
Multiple randomized clinical trials (including the CALORIES and NUTRIREA-2 trials) have demonstrated similar mortality between EN and PN when caloric delivery is matched. However, enteral nutrition consistently demonstrates statistically significant reductions in infectious complications (line sepsis, intra-abdominal abscesses, nosocomial pneumonia) and hospital/ICU length of stay. Consequently, EN is the uncontested primary route of nutrition support in the ICU.
Nutrition Risk Screening in the ICU: NUTRIC and NRS-2002
Traditional nutrition markers such as serum albumin, prealbumin, and body weight are completely invalid in critical illness because they reflect acute-phase systemic inflammation and capillary leak rather than somatic nutrition reserves. SCCM/ASPEN guidelines mandate utilizing validated ICU-specific nutrition risk tools to stratify patients:
1. The NUTRIC Score (Nutrition Risk in Critically Ill)
The NUTRIC score was developed specifically for mechanically ventilated ICU patients to determine who will experience adverse clinical outcomes (mortality, prolonged ventilation) if nutrition is withheld.
- Variable Range & Assigned Points
- Age (years) < 50 <50 < 50 (0 pts), 50 – 74 50\text{--}74 50 – 74 (1 pt), ≥ 75 \ge 75 ≥ 75 (2 pts)
APACHE II Score < 15 <15 < 15 (0 pts), 15 – 19 15\text{--}19 15 – 19 (1 pt), 20 – 27 20\text{--}27 20 – 27 (2 pts), ≥ 28 \ge 28 ≥ 28 (3 pts)
- SOFA Score < 6 <6 < 6 (0 pts), 6 – 9 6\text{--}9 6 – 9 (1 pt), ≥ 10 \ge 10 ≥ 10 (2 pts)
- Number of Co-morbidities 0 – 1 0\text{--}1 0 – 1 (0 pts), ≥ 2 \ge 2 ≥ 2 (1 pt)
Days from Hospital to ICU Admit 0 to < 1 day 0\text{ to }<1\text{ day} 0 to < 1 day (0 pts), ≥ 1 day \ge 1\text{ day} ≥ 1 day (1 pt)
Interleukin-6 (IL-6) Optional: < 400 <400 < 400 (0 pts), ≥ 400 \ge 400 ≥ 400 (1 pt)
Risk Stratification:
Without IL-6: Score ≥ 5 \ge 5 ≥ 5 indicates High Nutritional Risk ; score 0 – 4 0\text{--}4 0 – 4 indicates Low Nutritional Risk.
With IL-6: Score ≥ 6 \ge 6 ≥ 6 indicates High Nutritional Risk ; score 0 – 5 0\text{--}5 0 – 5 indicates Low Nutritional Risk.
Clinical Application: Patients at High Nutritional Risk derive substantial clinical benefit (reduced 28-day mortality) from rapid, aggressive attainment of target energy ( > 80 % >80\% > 80% of calculated goal) and protein within 48 to 72 hours. Patients at Low Nutritional Risk tolerate trophic feeding or delayed feeding for up to 7 days without excess mortality.
2. NRS-2002 (Nutritional Risk Screening 2002)
A score of ≥ 5 \ge 5 ≥ 5 points (combining impaired nutritional status, severity of disease, and age ≥ 70 \ge 70 ≥ 70 ) classifies the patient as high risk, necessitating prompt nutritional intervention.
Trophic Feeding Versus Full Enteral Feeding in ARDS
In acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), the gastrointestinal tract is vulnerable to hypoperfusion, while overfeeding risks excess carbon dioxide generation. The landmark EDEN Trial (Initial Trophic vs Full Enteral Feeding in Patients with Acute Lung Injury, Rice et al., JAMA 2012) addressed whether early full feeding is necessary.
Trophic Feeding Definition: Delivering minimal volume enteral nutrition—typically 10 to 20 kcal/hr 10\text{ to }20\text{ kcal/hr} 10 to 20 kcal/hr or up to 500 kcal/day 500\text{ kcal/day} 500 kcal/day (approximately 10 to 20 mL/hr 10\text{ to }20\text{ mL/hr} 10 to 20 mL/hr of a standard 1.0 kcal/mL 1.0\text{ kcal/mL} 1.0 kcal/mL formula).
Study Findings: Comparing initial trophic feeding for up to 6 days versus early full feeding advancing to goal within 48 hours demonstrated no significant differences in ventilator-free days (28 days), 60-day mortality, or infectious complications .
Complication Rates: The full-feeding cohort suffered significantly higher rates of gastrointestinal intolerance, including elevated gastric residual volumes ( p < 0.001 p < 0.001 p < 0.001 ), vomiting ( p < 0.001 p < 0.001 p < 0.001 ), and diarrhea.
Clinical Guideline Consensus: Trophic feeding was noninferior to early full feeding in the EDEN population and caused less gastrointestinal intolerance, but it is one acceptable strategy rather than a universal six-day mandate. The 2021 ASPEN guideline supports individualized delivery within about 12 to 25 kcal/kg/day 12\text{ to }25\text{ kcal/kg/day} 12 to 25 kcal/kg/day during the first 7 to 10 ICU days because trials have not shown a clear outcome advantage for forcing early goal energy.
Vasopressors, Shock, and Enteral Nutrition Safety
A critical exam topic is managing enteral nutrition in patients receiving vasoactive infusions. Vasopressors stimulate α 1 \alpha_1 α 1 -adrenergic receptors, shunting arterial blood away from the splanchnic circulation to maintain coronary and cerebral perfusion. Introducing enteral formula into an ischemic bowel increases local oxygen demand, precipitating Non-Occlusive Mesenteric Ischemia (NOMI) and transmural gangrene, a complication carrying an 80 % 80\% 80% mortality rate. [ HEMODYNAMIC STABILITY CHECKLIST ]
- │
- ┌─────────────────────────────┴─────────────────────────────┐
- ▼ ▼
- [ ACTIVE / UNRESUSCITATED SHOCK ] [ STABLE / RESUSCITATED SHOCK ]
- MAP < 65 mmHg • MAP sustained >= 65 mmHg
- Rapidly escalating vasopressors • Low, stable, or weaning pressors
- Rising serum lactate / worsening base deficit • Serum lactate normal or clearing
- Peripheral hypoperfusion, oliguria • Warm extremities, adequate urine
- │ │
- ▼ ▼
- [ HOLD ENTERAL NUTRITION ] [ INITIATE CAUTIOUS TROPHIC EN ]
- Strict NPO status • Continuous infusion at 10–20 mL/hr
- Bowel ischemia / NOMI risk extreme • Serial abdominal exams q4–6h
- Resume only after hemodynamics stabilize • Stop if abdominal pain/distension/shock
- Clinical Thresholds & ASPEN Recommendations
When to Withhold Enteral Nutrition:
Active, unresuscitated shock.
Mean Arterial Pressure (MAP) < 65 mmHg < 65\text{ mmHg} < 65 mmHg .
Rapidly escalating doses of vasopressors (e.g., steep upward titration of norepinephrine, epinephrine, or phenylephrine to sustain perfusion).
Rising serum lactate, severe base deficit, or clinical signs of mesenteric ischemia (abdominal rigidity, sudden ileus, high gastric residuals with bloody output).
When Enteral Nutrition is Safe to Initiate:
Fully fluid-resuscitated patient with a Mean Arterial Pressure sustained at ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg .
Receiving low-dose, stable, or downtitrating vasopressors (e.g., norepinephrine < 0.1 to 0.14 mcg/kg/min < 0.1\text{ to }0.14\text{ mcg/kg/min} < 0.1 to 0.14 mcg/kg/min , or stable low-dose vasopressin ≤ 0.03 units/min \le 0.03\text{ units/min} ≤ 0.03 units/min or phenylephrine).
Serum lactate is stable or downtrending.
Practice Rule: Start with trophic continuous infusion ( 10 – 20 mL/hr 10\text{--}20\text{ mL/hr} 10 – 20 mL/hr ) . Perform serial abdominal examinations every 4 to 6 hours. Immediately discontinue feeding if abdominal distension, localized tenderness, sudden increase in vasopressor requirement, or unexplained metabolic acidosis occurs.
Enteral Nutrition Delivery in Prone Positioning
Prone positioning for 16 to 24 hours daily 16\text{ to }24\text{ hours daily} 16 to 24 hours daily is an established evidence-based intervention that improves survival in severe ARDS ( P aO 2 / F iO 2 < 150 mmHg P_{\text{aO}_2}/F_{\text{iO}_2} < 150\text{ mmHg} P aO 2 / F iO 2 < 150 mmHg ). Many clinicians historically withheld enteral nutrition in the prone position due to fear of emesis, facial edema, and aspiration.
Safety and Feasibility: Modern multicenter clinical trials (including PROSEVA) confirmed that enteral nutrition can be delivered safely in the prone position without increasing ventilator-associated pneumonia or aspiration events.
Best Practice Protocol:
Position the bed in reverse Trendelenburg ( 10 – 25 ∘ 10\text{--}25^\circ 10 – 2 5 ∘ ) with head elevation to reduce regurgitation risk.
Utilize continuous pump infusion; avoid bolus or gravity feedings.
Initiate prokinetic agents (metoclopramide 10 mg 10\text{ mg} 10 mg IV q6h or erythromycin 125 – 250 mg 125\text{--}250\text{ mg} 125 – 250 mg IV q8h) if gastric residual volumes are elevated or gastrointestinal dysmotility is suspected.
Place a post-pyloric (small bowel) feeding tube if gastric feeding intolerance persists despite prokinetics.
Immune-Modulating Nutrition: Arginine and Glutamine Controversies
Specialized enteral and parenteral formulations containing pharmacological doses of specific nutrients have undergone extensive clinical investigation. For board examinations, precise contraindications must be mastered:
1. Arginine in Severe Sepsis and Septic Shock
Biochemical Pathway: L-Arginine serves as the sole substrate for nitric oxide synthases (NOS). In healthy tissue, endothelial NOS (eNOS) produces physiologic basal levels of nitric oxide ( N O NO NO ) to maintain microvascular blood flow.
Mechanistic Concern in Sepsis: Inflammatory signaling can alter inducible nitric oxide synthase activity, creating a theoretical concern that pharmacologic arginine could worsen vasodilation in an unstable patient. Clinical trials have not established this mechanism as a universal cause of harm: L-Arginine + O 2 + NADPH → iNOS L-Citrulline + N O + NADP + \text{L-Arginine} + \text{O}_2 + \text{NADPH} \xrightarrow{\text{iNOS}} \text{L-Citrulline} + \mathbf{NO} + \text{NADP}^+ L-Arginine + O 2 + NADPH iNOS L-Citrulline + NO + NADP +
Clinical Consequence: Overproduction of N O NO NO triggers profound, refractory peripheral vasodilation, collapse of vascular smooth muscle tone, severe refractory hypotension, and increased mortality.
Guideline Directive: SCCM/ASPEN guidance says immune-modulating formulas should not be used routinely in severe sepsis . This is a population-level recommendation based on inconsistent benefit, not proof that every exposure causes nitric-oxide-mediated collapse. Separately, enteral nutrition is held during refractory hypotension or escalating vasopressors regardless of formula.
2. Glutamine in Multi-Organ Dysfunction Syndrome (MODS)
Historical Rationale: Glutamine is a conditionally essential amino acid during stress, serving as the primary fuel for enterocytes, colonocytes, and lymphocytes, while acting as a precursor for glutathione synthesis.
The Landmark REDOXS Trial (Heyland et al., NEJM 2013): A rigorous, multicenter, randomized trial of 1,223 critically ill patients with multi-organ failure receiving high-dose enteral and parenteral glutamine (plus antioxidants). The trial demonstrated that glutamine supplementation was associated with a statistically significant INCREASE in 28-day mortality ( 32.4 % 32.4\% 32.4% vs. 27.2 % 27.2\% 27.2% ) and 6-month mortality ( 37.2 % 37.2\% 37.2% vs. 31.0 % 31.0\% 31.0% ) , particularly in patients with acute kidney injury and multi-organ failure.
Pathophysiological Mechanisms of Toxicity: Pharmacological doses overwhelmed damaged hepatic and renal urea clearance, causing severe hyperammonemia, accumulation of toxic glutamine metabolites, and cellular apoptosis in compromised parenchymal organs.
Guideline Directive: SCCM and ASPEN guidelines explicitly state that routine enteral or parenteral glutamine supplementation should NOT be administered to critically ill patients with multi-organ dysfunction syndrome or shock .